2025 / 06

Next Paper
DOI: 10.24075/brsmu.2025.057
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Features of the immune response to tumor alloantigens in the context of decreased clonal diversity of T cells

Korotkova MS , Persiyantseva NA , Kalinina AA , Khromykh LM , Kazansky DB
About authors

Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia

Correspondence should be addressed: Dmitry B. Kazansky
Kashirskoe shosse, 24, str. 15, Moscow, 115478, Russia; ur.xednay@1yksnazak

About paper

Funding: the study was financially supported by the Russian Science Foundation grant No. 22-15-00342-П (https://rscf.ru/project/22-15-00342/).

Author contribution: Korotkova MS — experimental work, analysis of the results; Persiyantseva NA — experimental work, analysis of the results, article editing; Kalinina AA — study planning, analysis and interpretation of the results, analysis of the available literature, article authoring and editing; Khromykh LM — article editing; Kazansky DB — study planning, analysis and interpretation of the results, analysis of the available literature, article editing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the N.N. Blokhin National Research Medical Center of Oncology of the Ministry of Health of the Russian Federation (Minutes No. 3-П10.06.2022 of June 10, 2022) and conducted in strict accordance with the provisions of Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes.

Received: 2025-10-06 Accepted: 2025-11-01 Published online: 2025-11-14
|
  1. Murphy K., Weaver C., Berg L. Janeway's Immunobiology. 10th ed. New York: W. W. Norton & Company, Inc, 2022.
  2. DeWolf S, Grinshpun B, Savage T, Lau SP, Obradovic A, Shonts B, et al. Quantifying size and diversity of the human T cell alloresponse. JCI Insight. 9; 3 (15): e121256.
  3. Tian G, Li M, Lv G. Analysis of T-Cell Receptor Repertoire in Transplantation: Fingerprint of T Cell-mediated Alloresponse. Front Immunol. 2022; 12: 778559.
  4. Lin CM, Gill RG. Direct and indirect allograft recognition: pathways dictating graft rejection mechanisms. Curr Opin Organ Transplant. 2016; 21 (1): 40–44.
  5. Kazansky DB. MHC restriction and allogeneic immune responses. J Immunotoxicol. 2008; 5 (4): 369–84.
  6. D'Orsogna LJ, Roelen DL, Doxiadis II, Claas FH. TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition. Immunogenetics. 2012; 64 (2): 77–85.
  7. Duneton C, Winterberg PD, Ford ML. Activation and regulation of alloreactive T cell immunity in solid organ transplantation. Nat Rev Nephrol. 2022; 18 (10): 663–76.
  8. Link-Rachner CS, Eugster A, Rücker-Braun E, Heidenreich F, Oelschlägel U, Dahl A, et al. T-cell receptor-α repertoire of CD8+ T cells following allogeneic stem cell transplantation using nextgeneration sequencing. Haematologica. 2019; 104 (3): 622–31.
  9. Tian G, Song S, Zhi Y, Qiu W, Chen Y, Sun X, et al. Alloreactive T cells temporarily increased in the peripheral blood of patients before liver allograft rejection. Liver Transpl. 2024; 30 (12): 1250–63.
  10. Mendoza Rojas A, Verhoeven JGHP, de Kuiper R, Clahsen-van Groningen MC, Boer K, Hesselink DA, et al. Alloreactive T cells to Assess Acute Rejection Risk in Kidney Transplant Recipients. Transplant Direct. 2023; 9 (5): e1478.
  11. Kim JY, Lei Z, Maienschein-Cline M, Chlipala GE, Balamurugan A, McDiarmid SV, et al. Longitudinal Analysis of the T-cell Receptor Repertoire in Graft-infiltrating Lymphocytes Following Hand Transplantation. Transplantation. 2021; 105 (7): 1502–9.
  12. Obata F, Yoshida K, Ikeda Y, Ohkubo M, Saito T, Takeuchi Y, et al. Clonality analysis of T cells mediating acute and chronic rejection in kidney allografts. Transpl Immunol. 2004; 13 (3): 233–7.
  13. Zeng G, Huang Y, Huang Y, Lyu Z, Lesniak D, Randhawa P. Antigen-Specificity of T Cell Infiltrates in Biopsies With T Cell-Mediated Rejection and BK Polyomavirus Viremia: Analysis by Next Generation Sequencing. Am J Transplant. 2016; 16 (11): 3131–8.
  14. Silaeva YY, Grinenko TS, Vagida MS, Kalinina AA, Khromykh LM, et al. Immune selection of tumor cells in TCR β-chain transgenic mice. J Immunotoxicol. 2014; 11 (4): 393–9.
  15. Grinenko TS, Pobezinskaya EL, Pobezinskii LA, Baturina IA, Zvezdova ES, Kazanskii DB. Suppression of primary allogenic response by CD8+ memory cells. Bull Exp Biol Med 2005; 140 (5): 545–9.
  16. Zamkova M, Kalinina A, Silaeva Y, Persiyantseva N, Bruter A, Deikin A, et al. Dominant role of the α-chain in rejection of tumor cells bearing a specific alloantigen in TCRα transgenic mice and in in vitro experiments. Oncotarget. 2019; 10: 4808–21.
  17. Pobezinskij LA, Pobezinskaya EL, Grinenko TS, CHervonskij AV, Kazanskij DB. Perifericheskij pul T-kletok CD8+ soderzhit limfocity s antigenspecificheskimi receptorami, raspoznayushchimi singennnye molekuly MNS klassa II. Ontogenez. 2004; 35 (3): 183–9.
  18. Silaeva Y, Kalinina A, Vagida M, Khromykh LM, Deikin AV, Ermolkevich TG, et al. Decrease in pool of T lymphocytes with surface phenotypes of effector and central memory cells under influence of TCR transgenic β-chain expression. Biochemistry (Moscow). 2013; 78: 549–59.
  19. Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, et al. SRplot: A free online platform for data visualization and graphing. PLoS ONE. 2023: 18 (11): e0294236.
  20. Listman JA, Rimm IJ, Wang Y, Geller MC, Tang JC, Ho S, et al. Plasticity of the T cell receptor repertoire in TCR beta-chain transgenic mice. Cell Immunol. 1996; 167 (1): 44–55.
  21. Ewing C, Allan W, Daly K, Hou S, Cole GA, Doherty PC, et al. Virus-specific CD8+ T-cell responses in mice transgenic for a T-cell receptor beta chain selected at random. J Virol. 1994; 68 (5): 3065–70.
  22. Jenkins MK, Moon JJ. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J Immunol. 2012; 88 (9): 4135–40.
  23. Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021; 39 (2): 154–73.
  24. Aran A, Garrigós L, Curigliano G, Cortés J, Martí M. Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality? Cancers (Basel). 2022; 14 (7): 1771.
  25. Wilczyński JR, Nowak M. Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors. In: Klink M., Szulc-Kielbik I, editors. Interaction of Immune and Cancer Cells. Experientia Supplementum, vol 113: Springer, 2022.
  26. Charles J, Mouret S, Challende I, Leccia MT, De Fraipont F, Perez S, et al. T-cell receptor diversity as a prognostic biomarker in melanoma patients. Pigment Cell Melanoma Res. 2020; 33 (4): 612–24.
  27. Qian L, Zhaohui Z, Yaping X, Zhentian L, Zhentao L, Qiqi W, et al. Blood T cell diversity associated with the prognosis of advanced non-small cell lung carcinoma treated with first-line pemetrexed based chemotherapy. Thorac Cancer. 2021; 12 (7): 997–1005.
  28. Abed A, Beasley AB, Reid AL, Law N, Calapre L, Millward M, et al. Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy. ESMO Open. 2023; 8 (6): 102066.
  29. Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology. 2012; 1 (4): 432–40.
  30. Jia Q, Zhou J, Chen G, Shi Y, Yu H, Guan P, et al. Diversity index of mucosal resident T lymphocyte repertoire predicts clinical prognosis in gastric cancer. Oncoimmunology. 2015; 4 (4): e1001230.
  31. Jin YB, Luo W, Zhang GY, Lin KR, Cui JH, Chen XP, et al. TCR repertoire profiling of tumors, adjacent normal tissues, and peripheral blood predicts survival in nasopharyngeal carcinoma. Cancer Immunol Immunother. 2018; 67 (11): 1719–30.
  32. Cui JH, Lin KR, Yuan SH, Jin YB, Chen XP, Su XK, Jet al. TCR Repertoire as a Novel Indicator for Immune Monitoring and Prognosis Assessment of Patients With Cervical Cancer. Front Immunol. 2018; 9: 2729.
  33. Fulop T, Larbi A, Pawelec G, Khalil A, Cohen AA, Hirokawa K, et al. Immunology of Aging: the Birth of Inflammaging. Clin Rev Allergy Immunol. 2023; 64 (2): 109–22.
  34. Britanova OV, Putintseva EV, Shugay M, Merzlyak EM, Turchaninova MA, Staroverov DB, et al. Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J Immunol. 2014; 192 (6): 2689–98.
  35. Shevyrev DV, Tereshchenko VP, Kozlov VA. Gomeostaticheskaya proliferaciya: ot normy k patologii. Rossijskij immunologicheskij zhurnal. 2018; 21 (2): 91–105. Russian.
  36. Montégut L, López-Otín C, Kroemer G. Aging and cancer. Mol Cancer 2024; 23 (1): 106.
  37. Kalinina AA, Ziganshin RK, Silaeva YY, Sharova NI, Nikonova MF, Persiyantseva NA, et al. Physiological and Functional Effects of Dominant Active TCRα Expression in Transgenic Mice. Int J Mol Sci. 2023; 24 (7): 6527.